B.r.a.h.m.s Gmbh

Sphingotec Gmbh

B.r.a.h.m.s Aktiengesellschaft

Adrenomed Ag

B.r.a.h.m.s. Diagnostica Gmbh

The General Hospital Corporation

Wacker Chemie Ag

4teen4 Pharmaceuticals Gmbh

Siltronic Ag

Angiobiomed Gmbh

Pam Theragnostics Gmbh

Andreas Bergmann

Joachim Struck

Nils G Morgenthaler

Jana Papassotiriou

Olle Melander

Andrea Ernst

Leong Loke Ng

Wolfgang Weglöhner

Monika Ühlein

Harald Hampel

Gilbert Vassart

Oliver Hartmann

Karl Lackner

Hans Rupprecht

Christoph Bickel

Stefan Blankenberg

Sabine Costagliola

Beat Müller

Stefan Anker

Thomas J Wang

Christopher Newton-Cheh

Christina Fischer-Schulz

Reiner Pech

Thomas Buschhardt

Detlef Schuppan

Stefan Faerber

Christian Fraunhofer

Simon Ehrenschwendtner

Siegfried Riess

Shaul Kornfeld

Wolfgang Wegl&ouml;hner

Renate Weckermann

Marita Willnich

Jörg-Michael Hollidt

Philip S Shepherd

Alan P Johnstone

Frauke Hein

Andrea Sparwaβer

Andrea Sparwasser

Natalia Rudovich

Christian Müller

Leong Ng

Andreas F H Pfeiffer

L Ng Leong

Andrea Sparwaßer

A method for (a) diagnosing or monitoring kidney function in subject or (b) diagnosing kidney dysfunction in a subject or (c) predicting or monitoring the risk of an adverse events in a diseased subject or (d) predicting or monitoring the success of a therapy or intervention comprising

Method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction

Subject matter of the present invention is an anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment or an anti-ADM non-Ig scaffold for use in therapy of a chronical or acute disease or acute condition of a patient for prevention or reduction of organ dysfunction or organ failure. In a preferred embodiment subject matter of the invention is an anti-ADM antibody or an anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold for use in therapy of a chronical or acute disease or acute condition of a patient for prevention or reduction of kidney dysfunction or kidney failure or liver dysfunction or liver failure.

Anti-adrenomedullin antibodies and pharmaceutical compositions thereof

An in vitro method for therapy follow-up in septic patients wherein the concentration of mature ADM 1-52 and/or mature ADM 1-52-Gly in a sample of bodily fluid of said septic patient is determined using an assay containing two binders that bind to two different regions within the region of mature adrenomedullin and/or adrenomedullin-Gly that is amino acid 21-52-amid SEQ ID No. 1 or amino acid 21-52-Gly SEQ ID No. 2 wherein each of said regions contains at least 4 or 5 amino acids, and further assays and calibration methods.

Adrenomedullin assays and methods for determining mature andrendomedullin

Subject of the present invention is a method for assessing a risk for getting a first cardiovascular event or assessing the risk for cardiovascular mortality in a subject, comprising: a) determining the level and/or the amount of Selenoprotein P and/or fragments thereof in a sample of said subject; b) correlating the determined level and/or the amount of Selenoprotein P and/or fragments thereof with the risk for getting a first cardiovascular event or assessing the risk for cardiovascular mortality in said subject.

Selenoprotein P for prediction of a first cardiovascular event

An in vitro method for therapy follow-up in septic patients wherein the concentration of mature ADM 1-52 and/or mature ADM 1-52-Gly in a sample of bodily fluid of said septic patient is determined using an assay containing two binders that bind to two different regions within the region of mature adrenomedullin and/or adrenomedullin-Gly that is aminoacid 21-52-amid SEQ ID No. 1 or aminoacid 21-52-Gly SEQ ID No. 2 wherein each of said regions contains at least 4 or 5 amino acids, and further assays and calibration methods.

Adrenomedullin assays and methods for determining mature adrenomedullin

The present invention is directed to methods for determining active DPP3 in a bodily fluid sample, an assay or kit for determining active DPP3 in a bodily fluid sample, a method for diagnosing a disease or condition in a subject accompanied by or related to necrotic processes and methods of treating or preventing said disease.

Methods for determining DPP3 and therapeutic methods

A method for modulating the adrenomedullin (ADM) activity of a patient by administering to the patient an anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment. The method may be used, for example, in therapy of a chronical or acute disease or acute condition of a patient for prevention or reduction of organ dysfunction or organ failure. In a preferred embodiment the method is for use in therapy of a chronical or acute disease or acute condition of a patient for prevention or reduction of kidney dysfunction or kidney failure or liver dysfunction or liver failure.

Method of modulating the adrenomedullin (ADM) activity of a patient by administering to the patient an anti-ADM antibody or fragment thereof that specifically binds to mature human ADM

The present invention relates to means and methods suitable for risk prediction of chronic kidney disease (CKD) using Pro-Enkephalin or fragments thereof as biomarker. The risk prediction methods of the invention are intended for healthy subjects and for subjects suffering from diseases such as hypertension, cardiovascular diseases and events, diabetes, metabolic syndrome, obesity, or autoimmune diseases. Subject matter of the invention is also a method of predicting the worsening or improvement of kidney function or dysfunction in healthy and diseased individuals.

Method for predicting the risk of incidence of chronic kidney disease

The present invention provides binder directed to and binding to a DPP3 protein or functional derivative thereof and its use in a method of prevention or treatment of diseases or acute conditions in a patient, wherein said disease or acute condition is associated with oxidative stress. With this context, specifically the present invention provides a binder being directed to and binding to an epitope according to SEQ ID NO.: 2, wherein said epitope is comprised in a DPP3 protein or a functional derivative thereof, and wherein said DPP3 binder recognizes and binds to at least three amino acids of SEQ ID NO.: 2.

DPP3 binder directed to and binding to specific DPP3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress

A method for determining the fat processing activity and/or predicting the risk of obesity in a subject involves determining the level of pro-neurotensin or fragments thereof of at least 5 amino acids in a bodily fluid obtained from the subject, and correlating the level of pro-neurotensin or fragments thereof with fat processing activity and/or the risk of incidence of obesity in the subject. An elevated level is indicative of enhanced fat processing activity and/or predictive for an enhanced risk of getting obesity.

Method for predicting the risk of obesity in a subject

In vitro methods such as in vitro diagnosis, prognosis and risk stratification of a patient having a primary disease, whereby the level of Procalcitonin (PCT) or fragment thereof in a sample of a bodily fluid of the patient is indicative for the risk of the patient to contract a further disease or medical condition. Assays for performing such methods and samples containing complex resulting from such methods.

Use of procalcitonin (PCT) in risk stratification and prognosis of patients with a primary, non-infectious disease

Subject of the present invention is an in vitro method for therapy follow-up in septic patients wherein the concentration of mature ADM 1-52 and/or mature ADM 1-52-Gly in a sample of bodily fluid of said septic patient is determined using an assay comprising two binders that bind to two different regions within the region of mature adrenomedullin and/or adrenomedullin-Gly that is aminoacid 21-52-amid SEQ ID No. 1 or aminoacid 21-52-Gly SEQ ID No. 2 wherein each of said regions comprises at least 4 or 5 amino acids. The invention further relates to assays and calibration methods.

Polysilicon chunks or granules are classified into size fractions using a mechanical screen having a profiled surface having peaks and valleys, and terminating in widening slots through which a polysilicon size fraction falls. The device is effective and the slots are resistant to clogging.

Screen plate for screening plants for mechanical classification of polysilicon

Growing community of inventors

Berlin, Germany

Andreas Bergmann